Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125
Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125
复制标题
术前CYFRA21-1联合CA125评估上皮性卵巢癌的诊断及预后价值
DOI：
10.1186/s13048-019-0587-0
复制
发表时间：
2019-11-25
影响因子：
4
通讯作者：
Ju, Shaoqing
中科院分区：
文献类型：
--
作者：
Jin, Chunjing;Yang, Minfeng;Ju, Shaoqing
越来越多的证据表明，肿瘤生物标志物细胞角蛋白19片段(CYFRA21-1)在多种癌症中具有重要意义。然而，其在上皮性卵巢癌(EOC)中的作用鲜有报道。在这项研究中，接收者操作特征(ROC)曲线被用来评估CYFRA21-1的诊断效率。采用Kaplan-Meier生存分析、单因素和多因素分析，分析CyFRA21-1水平与预后的关系。并分析了血清CYFRA21-1水平与不同临床病理变量的关系。同时检测标准血清标记物肿瘤抗原125(CA125)。结果表明，卵巢上皮性癌组织中CYFRA21-1的表达明显高于良性卵巢疾病组和正常对照组，与CA125相似(P<； 0.001)。CEFRA21-1的表达与CA125呈正相关(r = 0.201；P= 0.0032)。CYFRA21-1的表达与淋巴结转移和腹水显著相关(P<； 0.001)。经Kaplan-Meier分析，高表达的卵巢癌患者的中位生存期为42 月，低表达的卵巢癌患者的中位生存期为54 月(P<； 0.05)，而高表达和低表达的卵巢癌患者的中位生存期差异无统计学意义。单因素和多因素分析显示，CYFRA21-1是影响总生存期(OS)的不良预后因素，而CA125不是。我们的研究表明，在卵巢癌中，CYFRA21-1可作为一种良好的补充诊断生物标志物，并可能优于CA125作为一种预后指标。
Growing evidence indicates that the tumor biomarker cytokeratin 19 fragment (CYFRA21-1) is significant for a variety of cancers. However, its role in epithelial ovarian cancer (EOC) has rarely been reported. In this study, a receiver operating characteristic (ROC) curve was utilized to estimate the diagnostic efficiency of CYFRA21-1. The correlation between the CYFRA21-1 level and prognosis was analyzed by Kaplan-Meier survival analysis and univariable and multivariable analyses. The relationship between serum CYFRA21-1 levels and different clinicopathological variables was also analyzed. At the same time, the standard serum marker cancer antigen 125 (CA125) was measured. The results demonstrated that CYFRA21-1 expression was significantly increased in EOC compared with expression in benign ovarian diseases and healthy controls, which was similar to CA125 (P< 0.001). CYFRA21-1 expression was positively correlated with CA125 (r = 0.201;P= 0.0032). CYFRA21-1 expression was significantly correlated with lymph node metastasis and ascites (P< 0.001). Furthermore, the median survival time of EOC patients with high CYFRA21-1 expression was 42 months, compared with 54 months in the low CYFRA21-1 expression patients by Kaplan-Meier analysis (P< 0.05), while the high and low CA125 expression groups had no difference in median survival time. Univariate and multivariate analyses indicated that CYFRA21-1 was a poor prognostic factor associated with overall survival (OS), while CA125 was not. Our study indicates that CYFRA21-1 acts as a good complementary diagnostic biomarker and may be superior to CA125 as a prognostic indicator in EOC.